Post job

Zoetis main competitors are Novartis, Gilead Sciences, and Amgen.

Competitor Summary. See how Zoetis compares to its main competitors:

  • Johnson & Johnson has the most employees (134,500).
  • Employees at Novartis earn more than most of the competitors, with an average yearly salary of $112,479.
  • The oldest company is Pfizer, founded in 1849.
Work at Zoetis?
Share your experience

Zoetis vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1952
4.9
Parsippany-Troy Hills, NJ6$9.3B11,300
1891
4.6
Kenilworth, NJ31$64.2B74,000
2004
4.8
Lake Forest, IL1$4.5B19,000
1886
4.7
New Brunswick, NJ26$88.8B134,500
1980
4.8
Thousand Oaks, CA9$33.4B22,000
1987
4.5
Foster City, CA9$28.8B11,800
1988
4.9
Tarrytown, NY7$14.2B9,123
1997
4.7
Bothell, WA3$2.0B900
1975
4.4
Madison, NJ1$350.0M2,000
1996
4.9
East Hanover, NJ16$51.7B110,000
1954
4.9
Greenfield, IN2$4.4B10,200
1973
4.7
Pittsburgh, PA8$17.0B20,735
1956
4.7
Billerica, MA3$1.5B612
1987
4.7
South San Francisco, CA1$61.0B94,442
1981
4.8
Duluth, GA1$2.7B6,900
1849
4.5
New York, NY18$63.6B78,500
1974
4.0
West Lafayette, IN3$23.5M421
2006
4.7
Canton, MI1$126.0M150
1867
4.8
Hazelwood, MO5$1.0B3,400
1860
4.7
Madison, NJ1$22.4B49,732
1983
4.8
Westbrook, ME92$3.9B9,300

Zoetis competitors jobs

Zoetis jobs openings vs similar companies

If you’re looking for a job, here are the jobs openings at Zoetis and its competitors.

Zoetis remote jobs

Rate how well Zoetis differentiates itself from its competitors.

Zippia waving zebra

Zoetis salaries vs competitors

Among Zoetis competitors, employees at Novartis earn the most with an average yearly salary of $112,479.

Compare Zoetis salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Zoetis
$87,092$41.87-
Merck
$90,328$43.43-
Hospira
$64,435$30.98-
Johnson & Johnson
$76,686$36.87-
Amgen
$93,349$44.88-
Gilead Sciences
$99,828$47.99-

Compare Zoetis job title salaries vs competitors

CompanyHighest salaryHourly salary
Zoetis
$110,158$52.96
Bayer
$119,994$57.69
Novartis
$115,779$55.66
Amgen
$113,068$54.36
Merck
$112,318$54.00
Hospira
$111,106$53.42
Merial Limited
$110,125$52.94
Gilead Sciences
$110,022$52.90
Pfizer
$106,840$51.37
Regeneron
$106,313$51.11
Wyeth Biopharma
$105,683$50.81
Johnson & Johnson
$104,232$50.11
Elanco
$102,022$49.05
BASi
$100,420$48.28
IDEXX
$98,446$47.33
Lantheus
$97,961$47.10
Mallinckrodt
$91,156$43.82
Alpharma
$90,730$43.62
Roche Holding AG
$90,664$43.59
MMS
$85,389$41.05

Do you work at Zoetis?

Is Zoetis able to compete effectively with similar companies?

Zoetis jobs

Zoetis demographics vs competitors

Compare gender at Zoetis vs competitors

Job titleMaleFemale
BASi47%53%
IDEXX50%50%
Gilead Sciences56%44%
Amgen57%43%
Johnson & Johnson58%42%
Zoetis--
Male
Female
100%
75%
50%
25%
0%
0%
25%
50%
75%
100%

Compare race at Zoetis vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
49%24%7%15%5%
9.7
67%10%11%9%3%
7.4
44%20%8%23%6%
9.8
69%10%8%9%4%
9.6
54%16%10%15%4%
9.8
56%16%10%14%4%
9.8

Zoetis revenue vs competitors

Zoetis revenue is $9.3B. Among it's competitors, the company with the highest revenue is Johnson & Johnson, $88.8B . The company with the lowest revenue is BASi, $23.5M.

Zoetis and similar companies CEOs

CEOBio
Robert A. Bradway
Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Brian R. Bond
BASi

Daniel O’Day
Gilead Sciences

Jonathan J. Mazelsky
IDEXX

Mr. Mazelsky was appointed President and Chief Executive Officer of IDEXX on October 23, 2019. Prior to his appointment, Mr. Mazelsky served as IDEXX's Interim President and Chief Executive Officer beginning on June 28, 2019. Prior to his appointment as Interim President and Chief Executive Officer, he was an Executive Vice President responsible for our North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including our IDEXX VetLab® in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business. He joined IDEXX in August 2012 as Executive Vice President. Previously, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

Joaquin Duato
Johnson & Johnson

Mary Anne Heino
Lantheus

Mary Anne Hein is a President & CEO at LANTHEUS HOLDINGS, INC..

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Dr. Albert Bourla
Pfizer

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.

Roger D. Dansey
Seagen

Kristin Peck
Alpharma

What employees say about Zoetis's competitors

Employee reviews
profile
3.0
A zippia user wrote a review on Oct 2019
Pros of working at Zoetis

Excellent products

Cons of working at Zoetis

Management is misguided. Do not value employees. Will change territories and realign people on a whim. No security here.

Is this useful?1 people found this review helpful
Work at Zoetis? Share your experience

Zoetis competitors FAQs

Search for jobs